表紙
市場調査レポート

Abraxane - 膵臓癌治療薬: パイプライン分析および市場予測

Abraxane (Pancreatic cancer) - Analysis and Forecasts to 2020

発行 GlobalData 商品コード 237563
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
Abraxane - 膵臓癌治療薬: パイプライン分析および市場予測 Abraxane (Pancreatic cancer) - Analysis and Forecasts to 2020
出版日: 2011年12月31日 ページ情報: 英文 32 Pages
概要

当レポートでは、膵臓癌治療薬である Abraxane のパイプライン分析および市場予測を行っており、市場の特徴をはじめ、競合、パイプラインなどを評価分析し、将来の市場競争を盛り込んで、概略以下の構成でお届けします。

1 目次

  • 1.1 表一覧
  • 1.2 図一覧

2 イントロダクション

  • 2.1 膵臓癌
  • 2.2 膵臓癌治療薬市場
  • 2.3 疫学
  • 2.4 病因
  • 2.5 主に認められている危険因子
    • 2.5.1 喫煙
    • 2.5.2 年齢
    • 2.5.3 性別

2.5.4 家族の病歴

    • 2.5.5 その他の要因
    • 2.5.6 膵臓癌 予防
  • 2.6 GlobalData レポートガイダンス

3 膵臓癌: 市場特性

  • 3.1 膵臓癌 治療薬市場
  • 3.2 膵臓癌 治療薬市場 予測およびCAGR
  • 3.3 成長促進要因; 膵臓癌 治療薬市場
    • 3.3.1 高い発生率
    • 3.3.2 大きなアンメット・ニーズ
    • 3.3.3 稼働中のパイプライン

4 Tumor-Node-Metastases (TNM) 分類; 膵臓癌

  • 4.1 治療法オプション − 膵臓癌
  • 4.2 分類; 膵臓癌患者

5 Abraxane

  • 5.1 イントロダクション
  • 5.2 作用機序
  • 5.3 臨床研究
  • 5.4 売上影響因子; Abraxane
    • 5.4.1 高い有効性
    • 5.4.2 大きなアンメット・ニーズ
    • 5.4.3 オーファンドラッグ指定
    • 5.4.4 低い安全性プロファイル
  • 5.5 医薬品評価
    • 5.5.1 薬物のリスク・ベネフィット評価
    • 5.5.2 競争の激しさ
  • 5.6 売上 予測
    • 5.6.1 標的患者プール; Abraxane
    • 5.6.2 投薬
    • 5.6.3 市場浸透率
    • 5.6.4 治療の年間コスト
    • 5.6.5 売上予測; Abraxane

6 付録

  • 6.1 市場定義
  • 6.2 略語
  • 6.3 調査方法
    • 6.3.1 調査範囲
    • 6.3.2 二次調査
    • 6.3.3 予測
    • 6.3.4 薬の服用を認められた患者数
    • 6.3.5 治療薬の純市場浸透率
    • 6.3.6 年間純投薬量
    • 6.3.7 治療の年間コスト
  • 6.4 治療薬の売上予想モデル
  • 6.5 お問い合わせ
  • 6.6 免責事項
  • 6.7 情報ソース

表一覧

1.1 表一覧

  • 表 1: 膵臓癌, Estimated 発生率および死亡率, 長期予測
  • 表 2: 膵臓癌, TNM 分類
  • 表 3: 有効性 ; Abraxane − gemcitabine との併用
  • 表 4: 薬物のリスク・ベネフィット評価; Abraxane − gemcitabine との併用
  • 表 5: 相対的効力 comparision
  • 表 6: Abraxane, 膵臓癌, 世界市場, 売上 予測 ($m)
  • 表 7: Abraxane, 膵臓癌, 米国, 売上 予測 ($m)
  • 表 8: Abraxane, 膵臓癌, 英国, 売上 予測 ($m)
  • 表 9: Abraxane, 膵臓癌, フランス, 売上 予測 ($m)
  • 表 10: Abraxane, 膵臓癌, ドイツ, 売上 予測 ($m)
  • 表 11: Abraxane, 膵臓癌, イタリア, 売上 予測 ($m)
  • 表 12: Abraxane, 膵臓癌, スペイン, 売上 予測 ($m)

図一覧

1.2 図一覧

  • 図 1: 世界規模 発生率および死亡率 分布; 上位20位の癌 (%)
  • 図 2: タバコの総消費量, 米国, 過去30年間
  • 図 3: 平均発生率 (100,000人当たり), 膵臓癌, 米国, 男女共, 過去15年間
  • 図 4: 発生率 (100,000人当たり), 膵臓癌, 米国, 男女共, 今後20年間の予測
  • 図 5: 膵臓癌, 世界市場, 市場規模予測 ($m)
  • 図 6: 膵臓癌, 世界規模, 発生率 (100万人中), 長期予測
  • 図 7: 腫瘍学, 世界規模, 発生率 (100万人中), 長期予測
  • 図 8: 大別; 膵臓癌
  • 図 9: 分類; 膵臓癌患者
  • 図 10: 薬物モデルダイアグラム; Abraxane
  • 図 11: Abraxane, 膵臓癌, 世界市場, 売上 予測 ($m)
  • 図 12: Abraxane, 膵臓癌, 米国, 売上 予測 ($m)
  • 図 13: Abraxane, 膵臓癌, 英国, 売上 予測 ($m)
  • 図 14: Abraxane, 膵臓癌, フランス, 売上 予測 ($m)
  • 図 15: Abraxane, 膵臓癌, ドイツ, 売上 予測 ($m)
  • 図 16: Abraxane, 膵臓癌, イタリア, 売上 予測 ($m)
  • 図 17: Abraxane, 膵臓癌, スペイン, 売上 予測 ($m)
  • 図 18: Abraxane, 膵臓癌, 国別売上分布 (%), 予測
  • 図 19: 薬の服用を認められた患者

目次
Product Code: GDHC0004PCDVR

Summary

GlobalData's pharmaceuticals report, "Abraxane (Pancreatic cancer) - Analysis and Forecasts to 2020" provides Abraxane sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Pancreatic Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Abraxane including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Abraxane including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts from 2014-2020 for Abraxane in the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Abraxane, paclitaxel, Pancreatic cancer, Sales forecast, albumin bonded paclitaxel , phase III, phase 3, pipeline, GVAX, HyperAcute Pancreas, Irinotecan, Sutent, GV1001, Afinitor, Avastin, AMG479, Abraxane, Masitinib, Gemzar, Nexavar, S-1, Tarceva, Certican, Abraxis Bioscience.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Pancreatic Cancer
  • 2.2. Pancreatic Cancer Market
  • 2.3. Epidemiology
  • 2.4. Etiology
  • 2.5. The Main Recognized Risk factors
    • 2.5.1. Cigarette Smoking
    • 2.5.2. Age
    • 2.5.3. Gender
    • 2.5.4. Family History
    • 2.5.5. Other Factors
    • 2.5.6. Pancreatic Cancer Prevention
  • 2.6. GlobalData Report Guidance

3. Pancreatic Cancer: Market Characterization

  • 3.1. Pancreatic Cancer Disease Market
  • 3.2. Pancreatic Cancer Disease Market Forecasts and CAGR
  • 3.3. Drivers for the Pancreatic Cancer Disease Market
    • 3.3.1. High Incidence
    • 3.3.2. Large Unmet Need
    • 3.3.3. Active Pipeline

4. Tumor-Node-Metastases (TNM) Classification of Pancreatic Cancer

  • 4.1. Treatment Options in Pancreatic cancer
  • 4.2. Classification of Patients with Pancreatic Cancer

5. Abraxane

  • 5.1. Introduction
  • 5.2. Mechanism of Action
  • 5.3. Clinical Studies
  • 5.4. Factors Affecting Sales of Abraxane
    • 5.4.1. High Efficacy
    • 5.4.2. Large Unmet Need
    • 5.4.3. Orphan Drug Designation
    • 5.4.4. Low Safety Profile
  • 5.5. Drug Evaluation
    • 5.5.1. Drug Risk Benefit Score
    • 5.5.2. Intensity of Competition
  • 5.6. Sales Forecasts
    • 5.6.1. Target Patient Pool of Abraxane
    • 5.6.2. Dosing
    • 5.6.3. Market Penetration
    • 5.6.4. Annual Cost of Therapy
    • 5.6.5. Sales Projections of Abraxane

6. Appendix

  • 6.1. Market Definitions
  • 6.2. Abbreviations
  • 6.3. Research Methodology
    • 6.3.1. Coverage
    • 6.3.2. Secondary Research
    • 6.3.3. Forecasting
    • 6.3.4. Number of Patients Approved to Take the Drug
    • 6.3.5. Net Penetration of Drug
    • 6.3.6. Net Annual Dosing
    • 6.3.7. Annual Cost of Therapy
  • 6.4. Drug Sales Estimates Model
  • 6.5. Contact Us
  • 6.6. Disclaimer
  • 6.7. Sources

List of Tables

  • Table 1: Pancreatic cancer, Estimated Incidence and Mortality, 2008-2030
  • Table 2: Pancreatic Cancer, TNM Classification
  • Table 3: Efficacy of Abraxane in Combination gemcitabine
  • Table 4: Drug Risk Benefit Score of Abraxane in combination with gemcitabine
  • Table 5: Relative efficacy comparision
  • Table 6: Abraxane, Pancreatic Cancer, Global, Sales Forecasts ($m), 2014-2020
  • Table 7: Abraxane, Pancreatic Cancer, The US, Sales Forecasts ($m), 2014-2020
  • Table 8: Abraxane, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2015-2020
  • Table 9: Abraxane, Pancreatic Cancer, France, Sales Forecasts ($m), 2015-2020
  • Table 10: Abraxane, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2015-2020
  • Table 11: Abraxane, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2015-2020
  • Table 12: Abraxane, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2015-2020

List of Figures

  • Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2008
  • Figure 2: Total number of cigarettes consumed, The US, 1976-2006
  • Figure 3: Average Incidence Rate per 100,000, Pancreatic Cancer, the US, Both Sexes, 1992-2007
  • Figure 4: Incidence Rate per 100000, Pancreatic Cancer, the US, Both Sexes, 2010-2030
  • Figure 5: Pancreatic Cancer, Global, Market Size Forecasts ($m), 2010-2020
  • Figure 6: Pancreatic Cancer, Worldwide, Incidence (in million), 2008-2030
  • Figure 7: Oncology, Worldwide, Incidence (in million), 2008-2030
  • Figure 8: Broad Classification of Pancreatic Cancer
  • Figure 9: Classification of Patients with Pancreatic Cancer
  • Figure 10: Drug Model Diagram of Abraxane
  • Figure 11: Abraxane, Pancreatic Cancer, Global, Sales Forecasts ($m), 2014-2020
  • Figure 12: Abraxane, Pancreatic Cancer, The US, Sales Forecasts ($m), 2014-2020
  • Figure 13: Abraxane, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2015-2020
  • Figure 14: Abraxane, Pancreatic Cancer, France, Sales Forecasts ($m), 2015-2020
  • Figure 15: Abraxane, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2015-2020
  • Figure 16: Abraxane, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2015-2020
  • Figure 17: Abraxane, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2015-2020
  • Figure 18: Abraxane, Pancreatic Cancer, Sales Distribution by Country (%), 2020
  • Figure 19: Patients Approved for the Drug
Back to Top